These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22694794)

  • 1. Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization.
    Serrao A; Loglisci G; Salaroli A; Zacheo I; Alimena G; Breccia M
    Leuk Lymphoma; 2013 Feb; 54(2):411-2. PubMed ID: 22694794
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
    Hilmi M; Bally C; Burns R; Lorillon G; Bergeron A; Fenaux P; Ades L
    Ann Hematol; 2018 Mar; 97(3):541-542. PubMed ID: 29170809
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?
    Breccia M; Voso MT; Alimena G
    Leuk Res; 2013 Feb; 37(2):204-5. PubMed ID: 23174191
    [No Abstract]   [Full Text] [Related]  

  • 5. Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Niscola P; Tendas A; Abruzzese E; Caravita T; Cupelli L; Giovannini M; Scaramucci L; Siniscalchi A; Trawinska MM; de Fabritiis P
    Ann Hematol; 2017 Sep; 96(9):1591-1593. PubMed ID: 28702776
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.
    Niscola P; Siniscalchi A; Tendas A; Scaramucci L; Fratoni S; de Fabritiis P; Caravita T
    Ann Hematol; 2015 Oct; 94(10):1753-4. PubMed ID: 26088814
    [No Abstract]   [Full Text] [Related]  

  • 7. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 8. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia.
    Drummond MW; Pocock C; Boissinot M; Mills J; Brown J; Cauchy P; Cross NC; Hartley S; Kell J; Szubert A; Cockerill PN; Bowen DT
    Leukemia; 2014 Jul; 28(7):1570-2. PubMed ID: 24569776
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.
    Thorpe M; Montalvão A; Pierdomenico F; Moita F; Almeida A
    Leuk Res; 2012 Aug; 36(8):1071-3. PubMed ID: 22607959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].
    Wang L; Wang HX; Zhao J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):497. PubMed ID: 22213878
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
    Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
    Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
    [No Abstract]   [Full Text] [Related]  

  • 12. Sensitivity of cutaneous chronic myelomonocytic leukaemia lesions to hypomethylating treatment.
    Di Battista V; Matteucci C; Pulini S; Calabrese G; Quintini M; Moretti M; Ballanti S; Canino S; Di Bartolomeo P; Mecucci C
    Eur J Dermatol; 2017 Oct; 27(5):540-542. PubMed ID: 29084640
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].
    Manabe M; Okita J; Takakuwa T; Harada N; Aoyama Y; Kumura T; Ohta T; Furukawa Y; Mugitani A
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):781-4. PubMed ID: 25129095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.
    Shah D; Kumar R; Gaikazian S
    Haemophilia; 2014 Jan; 20(1):e92-4. PubMed ID: 24261579
    [No Abstract]   [Full Text] [Related]  

  • 15. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.
    Fianchi L; Criscuolo M; Breccia M; Maurillo L; Salvi F; Musto P; Mansueto G; Gaidano G; Finelli C; Aloe-Spiriti A; Santini V; Greco M; Hohaus S; Leone G; Voso MT
    Leuk Lymphoma; 2013 Mar; 54(3):658-61. PubMed ID: 22873829
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
    Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
    Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a role of decitabine in the treatment of myeloid sarcoma.
    Gornicec M; Wölfler A; Stanzel S; Sill H; Zebisch A
    Ann Hematol; 2017 Mar; 96(3):505-506. PubMed ID: 27817041
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia.
    Menter T; Schlageter M; Bastian L; Haberthür R; Rätz Bravo AE; Tzankov A
    Hematol Oncol; 2014 Mar; 32(1):47-51. PubMed ID: 23625339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
    Almeida AM; Pierdomenico F
    Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
    [No Abstract]   [Full Text] [Related]  

  • 20. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
    Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
    Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.